Vira Regen

6.8 million bone breaks occur annually in the US, costing up to $30,000 per patient and $2.7B in limited duty days per year. Current bone growth stimulators have ambiguous clinical efficacy, bulky designs, and have experienced FDA recalls, leaving patients with few effective noninvasive options.

OsteoVolt delivers preprogrammed, gene-targeted electric stimulation noninvasively using a capacitive coupling approach with less hardware than ultrasound and EMF competitors. By discovering specific signal combinations that control molecular genetics on demand, Vira Regen aims to significantly accelerate healing and expand into osteosarcoma, knee osteoarthritis, and osteoporosis.

Completed a successful 30-animal small animal study showing 50% faster bone fracture healing at week 3; filed two patents on novel stimulation signals; awarded $2M in non-dilutive DoD-MTEC funding; reclassified to Class II Medical Device 510(k) pathway; non-GLP large animal study in progress.

• 
  Altitude Labs serves up higher education for biotech founders

  BioSpace · Apr 29, 2026

  Altitude Labs, an offshoot of AI-focused techbio Recursion, is teaching scientists to build companies, one founder at a time.